EntryPoint Capital’s Immunocore IMCR Stock Holding History

EntryPoint Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$724K	Buy	+22,815	New	+$675K	0.18%	172
2025 Q4	–	Sell	-7,321	Closed	-$266K	–	755
2025 Q3	$266K	Buy	+7,321	New	+$249K	0.1%	414
2024 Q3	–	Sell	-11,408	Closed	-$387K	–	958
2024 Q2	$387K	Buy	+11,408	New	+$582K	0.18%	88

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EntryPoint Capital's IMCR Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Immunocore (IMCR) in Q2 2026: 22,815 shares worth $724K. The stake represents 0.18% of the portfolio and ranks #172 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in IMCR as recently as Q3 2025.

EntryPoint Capital first reported a position in IMCR in Q2 2024 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

EntryPoint Capital held 22,815 shares of Immunocore worth $724K as of Q2 2026.
Immunocore was a new EntryPoint Capital position in Q2 2026.
Immunocore made up 0.18% of EntryPoint Capital's portfolio in Q2 2026, its #172 holding.
EntryPoint Capital first reported a position in Immunocore in Q2 2024 and has held it in 3 quarters since.
136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.